スロバキア - スロバキア語 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

viiv healthcare bv, holandsko - zidovudín - 59 - immunopraeparata

スロバキア - スロバキア語 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

viatris limited, Írsko - epirubicín - 44 - cytostatica

スロバキア - スロバキア語 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - imatinib - 44 - cytostatica

欧州連合 - スロバキア語 - EMA (European Medicines Agency)

sandoz gmbh - infliximab - arthritis, psoriatic; psoriasis; crohn disease; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - imunosupresíva - liečba reumatoidná artritída, crohnova choroba, ulcerózna kolitída, ankylozujúcej spondylitídy, psoriatická artritída a psoriáza.

スロバキア - スロバキア語 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

viiv healthcare bv, holandsko - zidovudín - 59 - immunopraeparata

欧州連合 - スロバキア語 - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

欧州連合 - スロバキア語 - EMA (European Medicines Agency)

shionogi b.v. - lusutrombopag - trombocytopénia - antihemoragiká - mulpleo je indikovaný na liečbu ťažkej trombocytopénie u dospelých pacientov s chronickým ochorením pečene prechádza invazívne postupy.

欧州連合 - スロバキア語 - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombinantnej vírus vezikulárnej stomatitídy (kmeň indiana) s odstránením obálky glykoproteín, v súlade s zair ebolavirus (kmeň kikwit 1995) povrch glykoproteín - hemorrhagic fever, ebola - vakcíny - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. použitie ervebo by mali byť v súlade s oficiálne odporúčania.

欧州連合 - スロバキア語 - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

スロバキア - スロバキア語 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d. - fluóruracil - 44 - cytostatica